Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42300 | 0.82 | — | — | |
| SCHEMBL562965 | 0.82 | TDP1 (0.47) | LMNAFFAR3TDP1EYA2APP | |
| SCHEMBL5406160 | 0.82 | — | — | |
| SCHEMBL8356027 | 0.81 | LMNA (0.39) | LMNAFFAR3TDP1ALDH1A1ALDH2 | |
| SCHEMBL3714284 | 0.81 | LMNA (0.39) | LMNAFFAR3TDP1EYA2APP | |
| SCHEMBL5319721 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL329224 | 0.79 | — | — | |
| SCHEMBL9720322 | 0.79 | LMNA (0.46) | LMNAFFAR3ALDH1A1ALDH2MMP1 | |
| SCHEMBL672336 | 0.79 | — | — | |
| SCHEMBL150702 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5696069-A | MIXTURE CONTAINING A CATIONIC SURFACTANT, A LOW HLB NONIONIC SURFACTANT AND WATER | THE ANDREW JERGENS COMPANY (US) | 1997-12-09 | — | — | US | claimed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-106715463-A | Glycated peptide compositions and uses thereof | 苏塞克斯研究实验室 | 2017-05-24 | — | — | CN | disclosed |
| CN-102276698-B | MC4-R cyclopeptide agonist and application thereof | INST PHARM & TOXICOLOGY AMMS | 2014-02-26 | — | — | CN | disclosed |
| CN-102276698-A | MC4-R cyclopeptide agonist and application thereof | — | 2011-12-14 | — | — | CN | disclosed |
| CN-1245936-C | Detergent composition containing new glycine derivative and its use | KAO CORP (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1425364-A | Detergent composition containing new glycine derivative and its use | KAO CORP (JP) | 2003-06-25 | — | — | CN | disclosed |
| CN-1100751-C | Novel glycine derivatives, process for their preparation and their use | KAO CORP (JP) | 2003-02-05 | — | — | CN | disclosed |
| US-5696069-A | MIXTURE CONTAINING A CATIONIC SURFACTANT, A LOW HLB NONIONIC SURFACTANT AND WATER | THE ANDREW JERGENS COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| CN-1148846-A | Novel glycine derivatives, intermediates therefor and detergent compositions containing them | KAO CORP (JP) | 1997-04-30 | — | — | CN | disclosed |
| WO-1995005158-A1 | AEROSOL-FOAM PREPARATIONS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | LMNA 3639/4885FFAR3 199/4885TDP1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.